Merck May Sell Mature Drug Portfolio for $15B

Source: Reuters

May 01, 2014

Reuters sources are reporting that Merck is considering selling a large portfolio of off-patent drugs with a potential $15B pricetag.

Merck is working with an investment bank on the off-patent assets sale, which may attract interest from generic drugmakers, Reuters reports.

This news comes as Merck nears the potential sale of its $14B consumer healthcare business.

Merck's asset disposal efforts are in line with recent moves by drugmakers to sell off non-core divisions in order to better focus on core products.

 Read the Reuters press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments